Progress in endovascular therapies of TASC Ⅱ D aortoiliac occlusive disease
10.3760/cma.j.issn.1673-4203.2019.03.013
- VernacularTitle:TASCⅡD型主髂动脉闭塞症腔内治疗进展
- Author:
Xiaowei LI
1
;
Hongyong DUAN
Author Information
1. 山西医科大学
- Keywords:
Arterial occlusive diseases;
Arteriosclerosis obliterans;
Review;
TASCⅡ D aortoiliac occlusive disease;
Endovascular therapies
- From:
International Journal of Surgery
2019;46(3):194-199
- CountryChina
- Language:Chinese
-
Abstract:
Aortoiliac occlusive disease is a common and frequently-occurring disease of vascular surgery,and atherosclerosis is the main cause of its disease.Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC Ⅱ) D type of aortoiliac occlusive disease due to complex lesions,the preferred treatment method is aortobifemoral bypass.With the change of treatment concept,in-depth study of kiss stent,and the introduction of reconstruction of aortic bifurcation and integrated stent technology,endovascular therapies has achieved satisfactory short-term and long-term patency rates.At present,endovascular therapies has become the preferred treatment for TASC Ⅱ D aortoiliac occlusive disease.This article reviews the recent advances in endovascular therapies of TASC ⅡD aortoiliac occlusive disease.
